Service Overview

Ace Therapeutics offers a very diverse technology platform that facilitates target validation, enables rapid hit finding, hit confirmation, and supports lead series optimization. Ace Therapeutics' fragment-based drug discovery platform enables us to rapidly identify hits against the target of your choice. Starting with the gene of interest, Ace Therapeutics applies its fragment-based drug discovery expertise in protein science, assay biology, and medicinal chemistry to cost-effectively discover tractable leads.

Why Choose Ace Therapeutics?

Ace Therapeutics is a leading specialist in the field of ophthalmology and biophysical data generation, interpretation, and has a proven track record in fragment screening services for ophthalmic product development. We have a unique library of small molecule compound fragments for ocular diseases. In addition to this, our team of experts has established a range of primary screening techniques and used an X-ray crystallography platform to support real-time fragment processing. We provide the following fragment-based screening services to clients worldwide, including but not limited to.

• Surface Plasmon Resonance (SPR) Spectroscopy Screening

SPR is a powerful tool for studying biomolecular interactions in a sensitive and label-free assay format. It is capable of screening tens of thousands of compounds in a reasonable time frame. This technique requires only small amounts of protein and provides dissociation constants (Kd values) and, for tighter binders, on and off rates. However, for any SPR experiment, the protein or ligand must be immobilized. Ace Therapeutics currently offers an SPR service using our specially selected fragment library or your own library. We'll help you identify suitable fixation conditions.

• Nuclear Magnetic Resonance (NMR) Spectral Screening

NMR has become a method of choice for identifying fragments that specifically bind protein or nucleic acid targets, even weak ligands. This method can detect nM to mM interactions and provides structural information on the binding site. However, NMR requires relatively large amounts of protein and has size/solubility limitations on proteins (solubility between 0.1-1 mM).

• X-Ray Crystallographic Screening

The advantage of this approach is that compounds can be seen and evaluated. Therefore, it has a low false positive rate. In addition, binding affinity can be enhanced by using modeling techniques or purchasing related analogs. However, X-ray crystallography is a very time- and resource-intensive project, requiring large amounts of protein (10-50 mg of target protein with a purity greater than 95%). In addition, fragment ligands need to be soluble in the crystallization medium.

The Ace Therapeutics team consists of skilled pharmaceutical and computational chemists experienced in fragment-based drug discovery. We provide high-quality fragment-based screening services for small molecule compounds of global customers, so as to quickly synthesize target compounds. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

• Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Ligand-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Fragment-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Structure-Based Screening Services for Small Molecule Ophthalmic Drug Development
• High Throughput Screening Services for Small Molecule Ophthalmic Drug Development
• Computer-Aided Screening Services for Small Molecule Ophthalmic Drug Development
• Ocular Diseases Small Molecules Compound Library

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit